Population dynamics of HIV drug resistance among pre-treatment and treatmentexperienced persons with HIV during treatment scale-up in Uganda: a populationbased longitudinal study

Michael A. Martin¹, Steven James Reynolds^{2,3,4}, Charles Ssuuna², Brian T. Foley⁵, Fred Nalugoda², Thomas C. Quinn^{2,3,4}, Steven A. Kemp⁶, Margaret Nakalanzi², Edward Nelson Kankaka², Godfrey Kigozi², Robert Ssekubugu², Ravindra K. Gupta^{6,7}, Lucie Abeler-Dörner⁸, Joseph Kagaayi^{2,9}, Oliver Ratmann¹⁰, Christophe Fraser^{8,11}, Ronald Moses Galiwango², David Bonsall^{8,11,*}, M. Kate Grabowski^{1,2,13,*}, on behalf of the PANGEA-HIV Consortium and the Rakai Health Sciences Program

¹Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA 2Rakai Health Sciences Program, Kalisizo, Uganda 3Division of Infectious Disease, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA 4Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 5Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA 6 Department of Medicine, University of Cambridge, Cambridge, UK 7Africa Health Research Institute, KwaZulu-Natal, South Africa 8Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK ⁹Makerere University School of Public Health, Kampala, Uganda 10Department of Mathematics, Imperial College London, London, England, United Kingdom 11Pandemic Sciences Institute, University of Oxford, Oxford, UK

12Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

¹³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

*These authors contributed equally

*Corresponding author: mgrabow2@jhu.edu

Abstract

Background

Longitudinal data on the population prevalence of HIV drug resistance during scale-up of HIV treatment in Africa are extremely limited. We estimated trends in HIV drug resistance prevalence during ART program expansion from a population-based surveillance cohort in southern Uganda.

Methods

We analyzed data from Rakai Community Cohort Study participants aged 15-49 during four survey rounds conducted between 2012 (round 15) and 2019 (round 19). Consenting participants were tested for HIV and completed questionnaires. Persons living with HIV (PLHIV) provided samples for viral load quantification and virus deep-sequencing. Sequence data were used to predict resistance profiles. The prevalence of class-specific resistance and resistance-conferring substitutions were estimated using robust log-Poisson regression.

Findings

93,659 participant visits were contributed between 2012 and 2019, including 17,471 (18.65%) from PLHIV. Using deep-sequencing data from 3,713 pre-treatment participant-visits we estimated that the population prevalence of viremic NNRTI, NRTI, and PI resistance decreased significantly between 2012 and 2017 (PR = 0.38, 95% CI 0.25 – 0.57; 0.20, 95% CI 0.09 – 0.45; 0.19, 95% CI 0.09 – 0.39, respectively) with increasing viral suppression. Among viremic pretreatment PLHIV, the prevalence of NNRTI resistance increased two-fold ($PR = 1.96$, 95% CI 1.31-2.95) to 9.77% (7.35% - 12.97%) over the same time period. We did not observe an increase in NRTI or PI resistance in this population. The 2017 prevalence of NNRTI and NRTI resistance among viremic treatment-experienced PLHIV was 47.67% (95% CI 40.94% - 55.50%) and 36.55% (95% CI 30.14% - 44.31%), respectively. Single-class resistance predominated among resistant pre-treatment PLHIV (83.05%) whereas most treatment-experienced resistance was multi-class (76.65%). In 2017, 10.13% (95% CI 7.83%-13.63%) and 9.98% (95% CI 6.43%- 15.51%) of viremic pre-treatment and treatment-experienced PLHIV harbored the inT97A mutation.

Interpretation

Prevalence of HIV drug resistance among viremic PLHIV significantly increased with scale-up of ART programs. The prevalence of inT97A is potentially concerning considering the recent roll-out of dolutegravir-based regimens.

Funding

National Institutes of Health, the Bill & Melinda Gates Foundation, and the U.S. President's Emergence Plan for AIDS Relief through the Centers for Disease Control and Prevention.

Research in context

Evidence before the study

We searched PubMed for studies matching the keywords "hiv" "resistance" "longitudinal" "cohort" "population" published since 2004 (the beginning of antiretroviral therapy (ART) availability in sub-Saharan Africa) and identified 48 studies. We excluded 33 studies not based in sub-Saharan Africa, four studies primarily concerned with coinfection with other pathogens (e.g. HBV, *M. tuberculosis*), two studies concerned with insulin resistance, one sequencingmethods paper, and one paper concerned with host susceptibility to HIV infection. The remaining seven studies were not population-based meaning that the study population was not all persons but e.g. people living with HIV enrolled in care at a given clinic. We identified no previous longitudinal population-based cohort studies of HIV ART resistance in sub-Saharan Africa.

Added value of this study

We estimated the prevalence of drug resistance over four survey rounds of a population-based open-cohort study in southern Uganda between 2012 and 2019 during a period of intense treatment scale-up. We show that pre-treatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) among pre-treatment PLHIV increased significantly during the scale-up of ART. We further show that among viremic treatment-experienced individuals 48% and 37% harbored resistance to NNRTIs and nucleoside-reverse transcriptase inhibitors (NRTIs), the majority of which harbored multiclass resistance. While drug resistance among people living with viremic HIV increased, the overall prevalence of viremic HIV drug resistance in the population decreased by about two-thirds due to increasing population viral load suppression. The most common resistance mutation in our population was inT97A, a known compensatory mutation for integrase strand transfer inhibitor (INSTI) resistance. In contrast to other mutations, presence of inT97A did not depend on treatment status.

These results provide the first longitudinal population-based estimates of temporal trends in the prevalence of drug resistance during ART program expansion in a high-burden setting. Further, they provide critical insight into the landscape of prevalent drug resistance substitutions circulating in this population.

Implications of all the available evidence

Scale-up of HIV treatment has increased the prevalence of drug resistance mutations among viremic people living with HIV in sub-Saharan Africa. The relatively high prevalence of NNRTI resistance has prompted a recent shift to first-line regimens including dolutegravir (an INSTI) in combination with NRTIs. The high prevalence of an INSTI compensatory mutation in our population further warrants continuing monitoring of treatment failures and the prevalence of drug resistance in high burden settings.

Introduction

- Antiretroviral therapy (ART) effectively suppresses human immunodeficiency virus (HIV)
- 3 replication in persons living with HIV (PLHIV),¹ which slows disease progression² and prevents
- 4 viral transmission.³ With increased uptake of ART as well as interventions such as voluntary
5 medical male circumcision, global annual HIV incidence has fallen by nearly 40% since 2010
- 5 medical male circumcision, global annual HIV incidence has fallen by nearly 40% since 2010.⁴
-
- Viral resistance to ART can offset the clinical and public health impact of treatment scale-up.
- Drug resistance can be acquired when an individual initially infected with a susceptible viral
- population develops resistance following treatment exposure. This is more common when
- 10 treatment adherence is intermittent,⁵ but can occur despite high adherence.⁶ In low- and middle-
- income countries approximately 15% of individuals initiating therapy fail to achieve
- 12 suppression,⁷ which is largely due to resistance.⁸ Viral genomes with resistance-conferring
- mutations can be transmitted to individuals without a history of treatment, increasing their risk of
- 14 failing first-line treatment approximately five-fold.
-
- Cross-sectional studies in sub-Saharan Africa have revealed an increase in the prevalence of
- transmitted non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance during the roll-out
- of ART. A systematic meta-regression estimated that pre-treatment NNRTI resistance increased
- by 1.3% annually between 2001 and 2016 in this setting, reaching 10.1% in eastern Africa by
- 20 2016.¹⁰ Similarly, a systematic meta-analysis of studies conducted between 2017 and 2022 in
- 21 eastern Africa estimated the pooled prevalence of pre-treatment NNRTI resistance to be 9.4%.¹¹
- Longitudinal surveys of PLHIV who report to PEPFAR-supported clinics in Uganda, Kenya,
- Tanzania, and Nigeria (African Cohort Study) have further shown an increase in pre-treatment
- resistance from 8.8% (2013-2015) to 16.2% (2016-2019), of which most was NNRTI
- 25 resistance.¹² However, aggregation of findings across populations with different access to
- diagnostics and treatment and different clinical guidelines, limited temporal resolution, and a
- focus on PLHIV who are enrolled in care limit the generalizability of prior studies and introduce
- uncertainty in estimates of the burden of HIV drug resistance among PLHIV.
-
- Overall, there is a critical lack of longitudinal estimates of the prevalence of HIV drug resistance
	- in sub-Saharan Africa from population-based studies spanning the scale-up of ART. These
	- studies are essential to understanding the interaction between increased treatment uptake and
	- viral evolution and the implications of this interaction for the clinical and population burden of
	- HIV.
	-
	- Here, we used HIV deep-sequence data from 4,130 participant-visits collected over a nine-year
	- period from 3,456 PLHIV spanning a period of intense ART scale-up to identify temporal trends
	- in HIV drug resistance among pre-treatment and treatment experienced PLHIV in a population-
	- based open cohort study in southern Uganda. Through the study, first-line NNRTI-based
	- 40 regimens were the standard of care, often in combination with two NRTIs.¹³ We estimated the
	- prevalence of NNRTI, nucleoside reverse transcriptase inhibitor (NRTI), and protease inhibitor
	- (PI) resistance among PLHIV and among the entire study population using data from 3,713 pre-
	- treatment and 417 treatment-experienced PLHIV. We further evaluated temporal trends in
	- transmitted NNRTI resistance among 223 HIV-1 seroconverters. Finally, we assessed the
	- temporal dynamics of viral substitutions associated with drug resistance in pre-treatment and
	- treatment-experienced PLHIV.

Methods

Study design and participant selection

- The RCCS is an open population-based census and cohort study conducted at approximately 18-
- 24 month intervals (appendix pp 2-3) in agrarian (HIV prevalence $9-26\%^{14}$), semi-urban trading
- 52 (11-21%¹⁴), and Lake Victoria fishing $(38-43\frac{1}{14})$ communities in southern Uganda.¹⁵ At survey
- rounds households in participating communities are censused and residents aged 15-49 capable
- of providing informed consent (or assent if under 18) are invited to participate. Consenting
- participants are administered a structured questionnaire that obtains sociodemographic,
- behavioral, and health information, including self-reported past and current ART use. Voluntary
- HIV testing of participants is conducted using a rapid test algorithm¹⁶ and venous blood samples
- are taken for viral quantification and sequencing. Participants with serologically confirmed HIV
- infection were considered pre-treatment during a given round if they reported never having taken
- ARTs at that round and all prior rounds in which they participated. PLHIV were considered
- treatment-experienced during a given round if they reported using ART at that round or any earlier rounds.
-

Here, we used RCCS survey data from survey rounds 1 through 19, conducted between

November 5, 1994 and November 4, 2020, and HIV viral load and sequence data from survey

round 15, which began on August 10, 2011, through round 19 collected from a total of 43

communities. As they occur over a multi-year window, study rounds were plotted at the median

date over which the round occurred and referred to by the year of the median date (appendix p

). Reporting of this study adheres to the STROBE guidance¹⁷.

HIV viral load quantification

HIV viral load was measured on serum/plasma samples using the Abbott real-time m2000 assay

- (Abbott Laboratories). Viral load measurements were available for 1,959/3,499 (55.99%) of
- PLHIV in round 15 and 13,979/14,025 (99.67%) PLHIV in rounds 16 through 19. Participant
- visits from PLHIV in rounds 16 through 19 without viral load measurements (46/14,025, 0.33%)
- were dropped. Viral loads ≥ 1000 copies/mL were considered viremic. As 1,783/2,380 of pre-
- treatment participant-visits in round 16 through 19 were viremic, pre-treatment PLHIV in round
- 15 with missing viral load measurements were assumed to be viremic.
-

HIV deep sequencing

- Full-length HIV deep sequencing was conducted through the Phylogenetics and Networks for
- 82 Generalized HIV Epidemics in Africa consortium $(PANGEA-HIV)$. ^{18,19} As described
- 83 elsewhere, for survey rounds 15 and 16 sequencing on Illumina MiSeq and HiSeq platforms
- was attempted for participants who self-reported never having been on ART and either had a
- missing viral load or were known to be viremic (appendix p 4). For survey rounds 17 and 18 and
- select round 15 and 16 participant-visits, a total of 46.92% of all participant-visits (appendix p
- 87 7), sequencing of viremic samples was attempted using the veSEQ-HIV protocol.²¹ For round 19
- 88 sequencing data was only available for samples collected through May 17, 2022 ($N = 170/453$,
- 37.53% of participant visits) and therefore round 18 was used as an end-point for longitudinal
- 90 deep-sequence based analyses. Consensus sequences were generated using shiver²² and subtyped
- by identifying the most similar reference sequence and using the Recombination Identification
- 92 Program.²³

Identification of drug resistance substitutions

 A validated bioinformatic pipeline, drmSEQ, was used to identify amino acid substitutions 96 associated with reduced susceptibility to ART and predict individual drug class susceptibilities.²⁴

Paired-end reads were trimmed of adapters, primers, and low-quality bases and then filtered to

remove *pol* hypermutated sequences and non-HIV *pol* sequences. Reads were deduplicated using

- 99 Picard MarkDuplicates²⁵ and locally aligned to 142 HIV subtype references using blastx.²⁶ A
- manually-curated codon-restricted multiple-alignment of the references was used to lookup
- coordinates and mutations relative to HXB2 (GenBank: K03455.1). Only mutations supported by
- 102 a minimum of 10 PCR-deduplicated reads and by \geq 5% of reads spanning the corresponding site
- 103 were considered.²⁷ Amino acid substitutions were scored according to the Stanford University HIV Drug Resistance Database. Scores were summed to predict susceptibility to 25 HIV drugs
- (appendix p 8). ^{28–30} A score \geq 30 (intermediate/high-level) for a given drug was categorized as

resistant. Resistance was not predicted if less than half of the relevant positions for a given drug

had fewer than 10 reads. Samples with resistance to at least one drug within each class were

categorized as resistant to that class. Samples in which there was insufficient sequencing

- coverage for one or more drug within a class were not assigned a resistance categorization for
- 110 that class.
-
- *Outcome measures*
- The primary outcomes of this study were the prevalence of NNRTI, NRTI, and PI resistant
- genotypes among viremic pre-treatment and treatment-experienced PLHIV in the RCCS
- stratified by survey round. The overall RCCS population prevalence of viremic resistance,
- stratified by survey round and self-reported treatment status was also reported. We further
- estimated the prevalence of multi-class resistance among viremic round 18 participant visits with
- sufficient sequence data to predict resistance to all NNRTIs, NRTI, and PIs. The prevalence of
- resistance-conferring viral substitutions was estimated in round 15 through 19 among pre-
- treatment PLHIV with resistance predictions to all drugs and in rounds 17 and 18 among
- treatment-experienced PLHIV with resistance predictions to all drugs. For context, we estimated
- the population prevalence of PLHIV, viremic PLHIV, viremic PLHIV pre-treatment, and viremic
- treatment-experienced PLHIV in each round.
-

A sub-analysis was conducted among seroincident cases who were HIV negative at one RCCS

- visit and positive in the next during rounds 15 through 19 and self-reported never having been
- exposed to ART at their first positive RCCS visit. Among seroincident individuals with available
- genotypic NNRTI resistance data, we estimated the probability of harboring NNRTI resistance
- as a function of seroconversion round.
-
- We used inverse probability weighting based on availability of a viral load measurement
- (True/False), log10 copies/mL among samples with viral load measurements, community type
- (agrarian/fishing/trading, except for in the seroincident analysis due to small sample size), age
- category ((14,24]/(24,34]/(34,50]), and sex (M/F) stratified by survey round to account for
- missing sequence data among some viremic participant-visits and insufficient coverage to predict
- resistance among some sequenced participant-visits. See appendix pp 4-16 for detailed methods.
-
- *Statistical methods*

- 139 Statistical analyses were conducted in R v.4.3.1.³¹ Prevalence was estimated using Poisson
- 140 regression with a log-link and robust (sandwich) standard errors³² which were fit using the GLM
- 141 function in the native stats package, sandwich v.3.0.2³³ and lmtest v.0.9.40.³⁴ 95% confidence
- intervals and *p*-values ($\alpha = 0.05$) were calculated using the Wald method. χ^2 *p*-values ($\alpha =$
- 0.05) were calculated using the stats package in R. Repeated measures were evaluated using
- 144 geepack v.1.3.9³⁵ and an independent correlation structure was assumed as it generated estimates
- with the widest confidence intervals (appendix pp 17-21). Data analysis and visualization was
- 146 done using tidyverse v.2.0.0,³⁶ ggplo2 v.3.4.3,³⁷ cowplot v.1.1.1,³⁸ patchwork v. 1.1.3³⁹,
- 147 ggpattern v.1.0.1,⁴⁰ and ggrepel v.0.9.3.⁴¹ Readxl v.1.4.3⁴² and haven v.2.5.3⁴³ were used to parse
- data files.
-
- *Ethics*
- The RCCS is administered by the Rakai Health Sciences Program (RHSP) and has received
- ethical approval from the Uganda Virus Research Institute's Research and Ethics Committee
- (HS540), the Uganda National Council for Science and Technology (GC/127/15/11/137), and the
- Western Institutional Review Board, Olympia, WA (20031318). Participants provided written
- informed consent at each survey round.
-
- *Role of the funding source*
- The funders had no role in study design, collection, analysis, and interpretation of data; and no
- role in the writing of the report and decision to publish.
-

Results

- *Study population*
- Between August 10, 2011 and November 4, 2020, a total of 43,369 people participated in the
- RCCS, of whom 7,925 (18.27%) were PLHIV. Overall, the data contains 93,659 participant-
- visits, of which about a fifth were from PLHIV (table 1). Among participant-visits from PLHIV,
- 34.07% were contributed by viremic PLHIV and of these 86.96% were pre-treatment. A total of
- 320 PLHIV were identified as seroconverting with a last negative and first positive HIV test in
- consecutive survey rounds.
-
- Overall, HIV seroprevalence among RCCS participants slightly decreased from 20.37% (95% CI
- 19.78% 20.98%) in round 15 to 17.20% (95% CI 16.68% 17.74%) in round 19 (figure 1A,
- appendix p 22), while population prevalence of HIV viremia among persons with and without
- HIV decreased considerably from 8.14% (95% CI 7.75% 8.55%) to 2.34% (95% CI 2.14% -
- 2.57%) between round 16 and 19. These declines were accompanied by a nearly nine-fold
- decrease in the population prevalence of pre-treatment viremia over the study. The population
- prevalence of treatment-experienced viremia remained stable at around 1%.
-

178

179 **Figure 1: Longitudinal trends in HIV seroprevalence, population prevalence of pretreated HIV, and** 180 **prevalence of drug resistant HIV in the Rakai Community Cohort Study, 2012-2019.** (A) Estimated prevalence 181
181 of all HIV, viremic HIV, viremic pre-treatment HIV, and viremic treatment-experienced HIV in each roun 181 of all HIV, viremic HIV, viremic pre-treatment HIV, and viremic treatment-experienced HIV in each round. Due to 182 missing viral load data, prevalence of viremic HIV and viremic treatment-experienced HIV are not estim 182 missing viral load data, prevalence of viremic HIV and viremic treatment-experienced HIV are not estimated in the 183 2012 survey. (B, C) Estimated overall population prevalence of pre-treatment (B) and treatment-exper

2012 survey. (B, C) Estimated overall population prevalence of pre-treatment (B) and treatment-experienced (C) 184 NNRTI, NRTI, and PI resistance among viremi

184 NNRTI, NRTI, and PI resistance. (D, E) Estimated prevalence of NNRTI, NRTI, and PI resistance among viremic 185 pre-treatment PLHIV (D) and treatment-experienced (E) PLHIV. Estimates were generated using robust log-Poi 185 pre-treatment PLHIV (D) and treatment-experienced (E) PLHIV. Estimates were generated using robust log-Poisson
186 regression with robust standard errors. Error bars indicate the Wald 95% confidence interval for the me

186 regression with robust standard errors. Error bars indicate the Wald 95% confidence interval for the mean value
187 within each category. For visual clarity, points are jittered along the x-axis. PLHIV = people living

187 within each category. For visual clarity, points are jittered along the x-axis. PLHIV = people living with HIV.
188 NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhib

188 NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors. integrase inhibitors.

190

191 *Identification of resistance genotypes in deep-sequence data*

192 Sufficient sequence data were available to reliably genotype 4,130/5,953 (69.38%) viremic

193 participant visits (3,713/5,177 [71.72%] pre-treatment and 417/776 [53.74%] treatment-

194 experienced, table 2) for at least one drug. A total of 43.56%, 51.74%, 51.10%, and 59.92% were

195 successfully genotyped for all INSTIs, NNRTIs, NRTIs, and PIs, respectively (appendix pp 23-

- 196 26). Of those, <1% (INSTI), 12.37% (NNRTI), 6.71% (NRTI), and 1.85% (PI) had resistant
- 197 genotypes (appendix p 27). Given the low number of viremic samples with INSTI resistant
- 198 genotypes and the limited INSTI use in this setting over the study period we did not estimate the
- 199 prevalence of INSTI resistance in downstream analyses. Genotyping was successful for all
- 200 INSTIs, NNRTIs, NRTIs, and PIs for 39.24% of viremic participant visits (appendix p 29).
- 201 Missing genotype data was more common among samples with missing viral loads or with lower

202 viral loads when available and was slightly more common for female participants.

203

204 *Population prevalence of resistant genotypes*

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.14.23297021;](https://doi.org/10.1101/2023.10.14.23297021) this version posted October 15, 2023. The copyright holder for this preprint

- During round 15, the overall population prevalence of viremic pre-treatment NNRTI, NRTI, and
- PI resistant genotypes was estimated to be 0.65% (95% CI 0.49% 0.87%), 0.22% (95% CI
- 0.14% 0.34%), and 0.27% (95% CI 0.19% 0.40%), respectively (figure 1B, appendix p 30).
- Due to the decrease in the population prevalence of pre-treatment viremia, the overall population
- prevalence of NNRTI, NRTI, and PI resistant genotypes decreased significantly between study
- round 15 and 18 to 0.25% (95% CI 0.19% 0.33%), 0.04% (95% CI 0.02% 0.09%), and 0.05% (95% CI 0.03% - 0.10%), respectively.
-

In survey rounds 17 and 18 where sequence data were available for viremic pre-treatment and

- treatment-experienced PLHIV, the majority of participant visits with resistant genotypes were
- contributed by treatment-experienced PLHIV (appendix p 31). Specifically in round 18, 0.66%
- (95% CI 0.53%-0.81%) and 0.50% (95% CI 0.40%-0.64%) of participant visits were contributed
- by viremic treatment-experienced PLHIV with NNRTI and NRTI resistant genotypes,
- respectively (figure 1C, appendix p 32). Compared to PLHIV pre-treatment, treatment-
- experienced PLHIV contributed 2.64- and 12.50-fold more NNRTI and NRTI resistant
- genotypes. The total round 18 population prevalence of NNRTI and NRTI resistant genotypes,
- regardless of treatment status, was 0.90% (95% CI 0.76%-1.06%) and 0.51% (95% CI 0.41%-
- 0.64%), respectively (appendix p 33). The overall population prevalence of resistant genotypes was stable between round 17 and 18.
-
- *Prevalence of resistant genotypes among PLHIV*
- Despite the observed decrease in the population prevalence of resistant genotypes among pre-
- treatment PLHIV, this decrease was slower than that of all pre-treatment viremia. Consequently,
- the prevalence of NNRTI resistant genotypes among pre-treatment PLHIV approximately
- doubled between round 15 and round 18 (prevalence ratio 1.96, 95% CI 1.31-2.95, figure 1C,
- table 3), reaching an estimated prevalence of 9.77% (95% CI 7.35% 12.97%). This increase
- was observed among both men and women, across all age groups, and within all community
- types (appendix pp 34-36). In contrast, the prevalence of NRTI and PI resistant genotypes among
- viremic pre-treatment PLHIV remained stable and below 2.5% over the study period.
-
- Among seroincident cases between round 15 and 18, sequence data for NNRTI resistance
- substitutions was available for 223 PLHIV (69.69%). We estimated that the probability of
- harboring an NNRTI-resistant genotype among seroincident PLHIV was 9.95% (95% CI 4.65% -
- 21.28%) in round 18, which was similar to the probability in round 15 through 17 (appendix p
- 37). This analysis was underpowered to detect the difference in the prevalence of NNRTI-
- resistant genotypes observed in the population-level analysis (appendix p 38).
-
- Among viremic treatment-experienced round 18 participants, NNRTI and NRTI resistant
- genotypes were identified in 47.67 % (95 CI 40.94%-55.50%) and 36.55% (95% CI 30.14%-
- 44.31%), respectively, which was similar to the observed prevalence in round 17 (figure 1E,
- appendix p 39). Only 2.18% (95% CI 0.83%-5.76%) had viruses with PI resistance.
-
- *Multi-class resistance among PLHIV*
- Among viremic pre-treatment PLHIV with genotype-data available for all NNRTI, NRTI, and
- 249 PIs and resistance to at least one of these drug classes $(N=236)$, 83.05% harbored single-class
- resistance, of which the majority was NNRTI single-class resistance (figure 2A). In contrast,

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.14.23297021;](https://doi.org/10.1101/2023.10.14.23297021) this version posted October 15, 2023. The copyright holder for this preprint

251 among treatment-experienced participants $(N=197)$, less than a third had viruses with single-

252 class resistance and 72.59% harbored NNRTI/NRTI (/PI) multi-class resistant genotypes (figure

253 2B). In round 18 specifically, the prevalence of NNRTI multi-class resistance among viremic

254 PLHIV was estimated to be 1.37-folder higher than the prevalence of NNRTI single-class

255 resistance (figure 2C, appendix pp 40-41).

256

257 258 **Figure 2: Patterns of multi-class resistance in Rakai Community Cohort Study**. (A) Multi-class resistance 259 among 236 viremic pre-treatment PLHIV with genotype data for all NNRTIs, NRTIs, PIs, and resistance to at least one of these drug classes. (B) Multi-class resistance among 197 viremic treatment-experienced PLHIV with 260 one of these drug classes. (B) Multi-class resistance among 197 viremic treatment-experienced PLHIV with 261 senotype data for all NNRTIs, NRTIs, PIs, and resistance to at least one of these drug classes. Counts of eac 261 genotype data for all NNRTIs, NRTIs, PIs, and resistance to at least one of these drug classes. Counts of each 262 category are shown above the bar. (C) Estimated prevalence of NNRTI single-class and multi-class resistance in
263 cound 18 (2017) among viremic PLHIV. Estimates were generated using robust log-Poisson regression with 263 round 18 (2017) among viremic PLHIV. Estimates were generated using robust log-Poisson regression with robust
264 standard errors. Error bars indicate the Wald 95% confidence interval for the mean value within each cat 264 standard errors. Error bars indicate the Wald 95% confidence interval for the mean value within each category. Only
265 participant-visits with sequence data for all NNRTIs, NRTIs, and PIs were included. PLHIV = people 265 participant-visits with sequence data for all NNRTIs, NRTIs, and PIs were included. PLHIV = people living with
266 HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase i 266 HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. 267 PI = integrase inhibitors.

268

269 *Geographic heterogeneity in resistance*

270 We further stratified our estimates of the population prevalence of viremic resistance in round 18

271 by community type (agrarian, fishing, and trading) and individual community. The prevalence of

272 NNRTI and NRTI resistance was higher in fishing communities (2.35%, 95% CI 1.86% - 2.97%

273 and 1.46%, 95% CI 1.08% - 1.96%, respectively) compared to trading (0.59%, 95% CI 0.41% -

- 274 0.85% and 0.27%, 95% CI 0.16% 0.46% or agrarian (0.49%, 95% CI 0.35% 0.69% and
- 275 0.27% 95% CI 0.18% 0.43%) communities (figure 3, appendix p 42).
- 276

Further, among fishing communities, the population prevalence of NNRTI and NRTI resistance

was greater than expected based on the prevalence of viremia in fishing communities and the

- average prevalence of resistant genotypes among all viremic PLHIV regardless of community (figure 3B,C, appendix p 42).
-

Prevalence of amino acid substitutions associated with drug resistance

Among participant-visits with genotyping data available for all drugs, the most common drug

- resistance substitutions in the reverse transcriptase gene (those giving rise to NNRTI and NRTI
- resistance) were rtK103N (NNRTI, 8.82%), rtM184V (NRTI, 6.93%), and rtE138A (NNRTI and
- NRTI, 4.32%, figure 4A). Among viremic pre-treatment PLHIV, the prevalence of rtK103N was
- 7.27% (95% CI 5.17% 10.20%) in round 18, a 2.36-fold (95% CI 1.13 4.92) increase from
- round 15 (figure 4B,C, appendix pp 45-46). We observed no difference in the pre-treatment
- prevalence of rtK103N between men and women (appendix p 47). Unsurprisingly, rtK103N was
- more common among viremic treatment-experienced individuals (26.73%, 95% CI 20.93% -

304 34.14%, figure 4D, appendix p 48). However, rtM184V was the most common substitution in 305 this population and was present in approximately a third of treatment-experienced individuals. 306

307
308

308 **Figure 4: Amino acid substitutions underlying predicted drug resistance.** (A) Number of sequenced participant 309 visits (N=4,130) in which each drug resistance substitution is observed. Data points are colored based on the gene in which each substitution occurs (integrase shown in green, protease shown in pink, and reverse tra which each substitution occurs (integrase shown in green, protease shown in pink, and reverse transcriptase shown 311 in blue). Within gene substitutions are ordered based on the number of observations. (B) Prevalence ratio comparing 312 survey round 18 to survey round 15 of the 15 most prevalent drug resistance substitutions in pre-treatment PLHIV, sorted by round 18 prevalence. (C) Prevalence in survey round 18 of the 15 most prevalent substitutions 313 sorted by round 18 prevalence. (C) Prevalence in survey round 18 of the 15 most prevalent substitutions in viremic pre-treatment PLHIV sorted by prevalence. (D) Prevalence in survey round 18 of the 15 most prevalent su 314 pre-treatment PLHIV sorted by prevalence. (D) Prevalence in survey round 18 of the 15 most prevalent substitutions in treatment-experienced PLHIV sorted by prevalence. (E) Prevalence of all observed resistant substitut 315 in treatment-experienced PLHIV sorted by prevalence. (E) Prevalence of all observed resistant substitutions among
316 viremic pre-treatment PLHIV (X-axis) and viremic treatment-experienced PLHIV (Y-axis). Select substi 316 viremic pre-treatment PLHIV (X-axis) and viremic treatment-experienced PLHIV (Y-axis). Select substitutions are
317 labelled. Estimates generated using robust log-Poisson regression. The Wald method was used to generat 317 labelled. Estimates generated using robust log-Poisson regression. The Wald method was used to generate 95% confidence intervals around the mean value. Data points are colored by gene as in (A) and genes are further 318 confidence intervals around the mean value. Data points are colored by gene as in (A) and genes are further indicated by point shapes (integrase shown as a diamond, protease as a square, and reverse transcriptase as a 319 indicated by point shapes (integrase shown as a diamond, protease as a square, and reverse transcriptase as a triangle). PLHIV = people living with HIV. RT = reverse transcriptase. IN = integrase. PR = protease. triangle). PLHIV = people living with HIV. RT = reverse transcriptase. IN = integrase. PR = protease. 321

- 322 Overwhelmingly, the most frequent resistance associated substitution was inT97A (11.09% of
- 323 viremic genotyped participant-visits, figure 4A). This substitution is canonically associated with
- 324 integrase strand transfer inhibitors (INSTI) resistance, although its impacts in the absence of
- 325 other INSTI mutations are thought to be minimal.⁴⁴ Overall this substitution was present in
- 326 10.33% (95% CI 7.83% 13.63%) of viremic pre-treatment PLHIV in round 18, which was
- 327 similar to its prevalence in round 15 (PR 1.32, 95% CI 0.86 2.02, figure 5B,C). In contrast to
- 328 other drug resistance substitutions, the prevalence of inT97A was nearly identical among viremic
-

among viremic pre-treatment PLHIV was robust to the assumed correlation structure between

repeated measures and observed irrespective of sex, age, community type, or HIV-1 group M

subtype (appendix pp 49-53). We did not observe an increased viral load among pre-treatment

individuals with in97A as opposed to in97T (appendix p 54). Finally, within-host frequency and

number of deduplicated supporting reads were comparable between T97A and all other

resistance associated substitutions.

Discussion

Here, we report on trends in the prevalence of HIV drug resistance among viremic individuals in

a longitudinal population-based open cohort study in southern Uganda during a period of

 intensive scale-up of antiretroviral treatment programs. HIV deep-sequence data were available for survey round 15 (2012) through 18 (2017) and partially for survey round 19 (2019). Due to

increased treatment uptake and significantly lower HIV incidence, the population prevalence of

pre-treatment NNRTI and NRTI resistance decreased by 62% and 80% among all participants

regardless of HIV status, respectively, between survey round 15 (2012) and 18 (2017). In survey

round 18, 0.25% and 0.04% of all participant visits were contributed by viremic pre-treatment

PLHIV with NNRTI and NRTI resistant viremia. However, this decrease was slower than that of

susceptible viremia and the prevalence of NNRTI resistance approximately doubled among pre-

treatment PLHIV over this time period, reaching nearly 10% by round 18. Resistance was more

prevalent among viremic treatment-experienced PLHIV of whom 48% and 37% harbored

NNRTI and NRTI resistance (round 18). We did not observe a decrease in the prevalence of

resistance among viremic treatment-experienced PLHIV between round 17 and 18. Despite a

lack of INSTI use in this cohort over the study period, approximately 10% of viremic pre-

treatment and treatment-experienced PLHIV harbored the inT97A substitution.

 The estimated increase in NNRTI resistance among viremic pre-treatment PLHIV from 5% in survey round 15 to 10% in round 18 is consistent with a cross-sectional meta-analysis of

357 predominantly clinic-based studies conducted in eastern Africa between 2017 and 2022¹¹ and

with the longitudinal prevalence estimates reported in a meta-analysis of cross-sectional studies

 $f(359)$ from eastern Africa.¹⁰ Our estimated prevalence of pre-treatment NNRTI resistance is slightly

 δ 1 dess than what was observed in a recent analysis of 291 care-seeking PLHIV in Uganda, ¹² which

likely reflects differences in the burden of resistance between those who are, and aren't engaged

in care and highlights the value in estimates from population-based cohort studies.

Among pre-treatment PLHIV, NNRTI resistance was largely driven by the rtK103N substitution

(efavirenz and nevirapine resistance⁴⁵) which increased in prevalence six-fold over the study

period and was present in 7% and 26% of viremic pre-treatment and treatment-experienced

PLHIV during survey round 18. The high prevalence of rtK103N among pre-treatment PLHIV

indicates that this substitution can persist without reversion in the absence of treatment,

369 consistent with a limited fitness cost.⁴⁶ NNRTI resistance in this cohort may be partially attributable to single-dose nevirapine treatment of pregnant women used to prevent mother-to-

371 child-transmission in Uganda between 2000 and $2006⁴⁷$ which has been shown to increase

372 resistance in women and children.⁴⁸

 Approximately half of participants who remained viremic after treatment initiation in this study were not found to harbor resistance. This suggests that first-line regimens may remain effective

in a subset of this population and additional adherence counseling may be needed to increase

- 377 levels of viral suppression.⁴⁹
-

 Among treatment-experienced individuals with resistant genotypes, most harbored NNRTI/NRTI multi-class resistance, followed by NNRTI single-class resistance. This suggests that within individuals NNRTI resistance arises first followed by resistance to NRTI, consistent with 382 previous work.^{3,50,51} In contrast, NNRTI mono-resistance dominated among pre-treatment PLHIV. As the prevalence of multi-class resistance among viremic PLHIV was approximately 1.35-times that of single-class resistance, the risk of exposure to multi-class resistance is expected to be greater than that of mono-resistance. Subsequently, a subset of pre-treatment mono-resistant PLHIV may have been infected by a multi-class resistant genotype which reverted to wild-type or alternatively NNRTI/NRTI resistant virus may be less transmissible than NNRTI mono-resistant virus. The former hypothesis would imply that archived NRTI resistance

- is more prevalent than apparent from sequencing viral RNA. This is potentially concerning as
- archived NRTI resistance could result in de factor mono-therapy under the current first-line
- NRTI/DTG treatment regimen. Encouragingly, DTG monotherapy has been shown to be robust
- to resistance evolution for at least 192 weeks.⁵² However, treatment adherence was extremely
- high (>99%) in this cohort and these results may not hold in other settings.
-

Approximately a tenth of sequenced participant-visits from recent survey rounds harbored the

- 396 inT97A substitution. Alone, inT97A has minimal impact on susceptibility to most INSTIs,⁴⁴
- however, in combination with other substitutions (e.g. inG140S and inQ148H) it can
- 398 significantly increase resistance.^{53–55} The addition of inT97A to a inG140S+inQ148H backbone
- results in an increase from a three-fold to a 28-fold change in DTG EC50 compared to wild-
- 400 type.⁵⁴ Further, there is preliminary evidence that inT97A may be under selection as an HLA-
- 401 escape mutation.⁵⁶
-

 Lastly, previous work from our group has highlighted the outsized burden of HIV in fishing communities¹⁴, we here report that these communities also have an unusually high prevalence of NNRTI and NRTI resistance. Fishing communities are known have high rates of immigration of 406 PLHIV^{57,58} and recent in-migrants into RCCS communities are less likely to be engaged in care

- 407 and suppressed as compared to long-term residents.⁵⁹ Mobile populations of PLHIV may therefore suffer from difficulty accessing treatment leading to treatment interruptions, which can
- foster acquired evolution.
-

There are some important limitations of this work. Due to unknown HIV sero-status among non-

- participating residents of RCCS communities, we did not attempt to generalize our results
- beyond study participants. Younger individuals, men, and residents of trading communities have
- 414 previously been reported to be less likely to participate in RCCS surveys.¹⁵ Importantly, NNRTI
- resistance is not significantly associated with these epidemiological sub-groups and we therefore
- expect participation biases to be minimal. Further, the RCCS only routinely collects self-reported treatment status, which can lead to misclassification of participants. Prior work has demonstrated
- 418 that 11% of self-reported ART-naïve participants had antivirals in their blood.⁶⁰ Given the
- significant differences observed in the mutational profiles based on self-reported treatment status
- and the consistency of these results with estimates of the fitness impact of mutations in the
- 421 absence of treatment, ⁴⁶ we expect that these biases in the current study are minimal. As this

- work is based on deep-sequence data generated from viral RNA in plasma samples, we were
- only able to identify resistance substitutions among viremic PLHIV. As such, our population
- prevalence estimates are necessarily an underestimate of the true values as a subset of suppressed
- PLHIV may harbor resistance if they have successfully transitioned to second-line therapy or are
- transiently suppressed shortly after initiating treatment. The latter scenario may be more
- pronounced in recent survey rounds as treatment scale-up has likely increased the number of
- treatment-experienced individuals who have very recently initiated treatment.
-
- This study adds critical context to our understanding of the HIV epidemic in southern Uganda
- and to the impact of treatment expansion on the population burden of HIV resistance. While HIV
- drug resistance increased among pre-treated individuals, increasing VL suppression in the
- population as a result of treatment was associated with declines in the overall prevalence of
- viremic resistant HIV in the population.
-
- Our results further suggest that given the relatively high prevalence of viremic treatment-
- experienced PLHIV with multi-class NNRTI/NRTI resistance, archived NRTI resistance among
- pre-treatment PLHIV may be more common than is apparent based on sequencing of viral RNA.
- Future studies that use proviral sequencing to identify archived resistance directly are needed to
- evaluate this hypothesis. The high-prevalence of inT97A, which appears to be an important
- compensatory mutation for DTG resistance and has little to no negative fitness impacts in the
- absence of drug, is concerning. Overall, these findings stress the importance of continued viral
- sequence-based monitoring of resistance mutations among PLHIV during the ongoing scale-up
- of DTG and NRTI-based treatment regimens.
-

Acknowledgements

- We thank the Rakai Health Sciences Program and the participants of the Rakai Community
- Cohort Study for making this research possible. We thank members of the PANGEA-HIV
- consortium, the Johns Hopkins University Infectious Disease Dynamics group, and the NIAID
- Laboratory of Immunoregulation International HIV/STD Section at the Johns Hopkins
- University School of Medicine for helpful feedback on this work. This work was supported by
- the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases
- (U01AI051171, U01AI075115, UM1AI069530-16, R01AI087409, U01AI100031,
- R01AI110324, R01AI114438, K25AI114461, R01AI123002, K01AI125086, R01AI128779,
- R01AI143333, R21AI145682, R01AI155080, ZIAAI001040), NIH National Institute of Child
- Health and Development (R01HD038883, R01HD050180, R01HD070769, R01HD091003),
- NIH National Heart, Lung, and Blood Institute (R01HL152813), NIAID Division of Intramural
- Research, the Fogarty International Center (D43TW009578, D43TW010557), the Johns Hopkins
- University Center for AIDS Research (P30AI094189), the Bill & Melinda Gates Foundation
- (OPP1175094, OPP1084362), and the U.S. President's Emergency Plan for AIDS Relief through
- the Centers for Disease Control and Prevention (NU2GGH000817).
-

Data sharing

- Code to reproduce all analyses and visualizations as well as de-identified resistance and limited
- 465 patient metadata are available at https://github.com/m-a-martin/rccs hiv resistance r15 r19.
- Due to privacy concerns we are unable to share individual-level data on community of residence.
-

Declaration of interests

- We declare no competing interests.
-

References

- 1 Hoenigl M, Chaillon A, Moore DJ, *et al.* Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. *Sci Rep* 2016; **6**: 32947.
- 2 Kelley CF, Kitchen CMR, Hunt PW, *et al.* Incomplete Peripheral CD4 ⁺ Cell Count
- Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral Treatment. *Clin Infect Dis* 2009; **48**: 787–94.
- 3 Cohen MS, Chen YQ, McCauley M, *et al.* Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med* 2016; **375**: 830–9.
- 4 UNAIDS. AIDSinfo. https://aidsinfo.unaids.org.

 5 Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance. *Clin Infect Dis* 2003; **37**: 1112–8.

- 6 Bangsberg DR, Charlebois ED, Grant RM, *et al.* High levels of adherence do not prevent accumulation of HIV drug resistance mutations: *AIDS* 2003; **17**: 1925–32.
- 7 Boender TS, Sigaloff KCE, McMahon JH, *et al.* Long-term Virological Outcomes of First- Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2015; **61**: 1453–61.
- 8 Gregson J, Tang M, Ndembi N, *et al.* Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. *Lancet Infect Dis* 2016; **16**: 565–75.
- 9 Beck IA, Levine M, McGrath CJ, *et al.* Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya. *eClinicalMedicine* 2020; **18**: 100239.
- 10Gupta RK, Gregson J, Parkin N, *et al.* HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *Lancet Infect Dis* 2018; **18**: 346–55.
- 11Ntamatungiro AJ, Kagura J, Weisser M, Francis JM. Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis. *J Antimicrob Chemother* 2022; **77**: 3231–41.

 12Crowell TA, Danboise B, Parikh A, *et al.* Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries. *Clin Infect Dis* 2021; **73**: e2311–22.

- 13Consolidated guidelines for the prevention and treatment of HIV in Uganda. 2018; published online Sept.
- 14Chang LW, Grabowski MK, Ssekubugu R, *et al.* Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study. *Lancet HIV* 2016; **3**: e388–96.
- 15Grabowski MK, Serwadda DM, Gray RH, *et al.* HIV Prevention Efforts and Incidence of HIV in Uganda. *N Engl J Med* 2017; **377**: 2154–66.
- 16Kagulire SC, Opendi P, Stamper PD, *et al.* Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. *Int J STD AIDS* 2011; **22**: 308–9.
- 17Elm EV, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; **335**: 806–8.
- 18Pillay D, Herbeck J, Cohen MS, *et al.* PANGEA-HIV: phylogenetics for generalised epidemics in Africa. *Lancet Infect Dis* 2015; **15**: 259–61.
- 19Abeler-Dörner L, Grabowski MK, Rambaut A, Pillay D, Fraser C. PANGEA-HIV 2:
- Phylogenetics And Networks for Generalised Epidemics in Africa. *Curr Opin HIV AIDS* 2019; **14**: 173–80.
- 20Monod M, Brizzi A, Ssekubugu R, *et al.* Growing gender disparity in HIV infection in Africa: sources and policy implications. .
- 21Bonsall D, Golubchik T, de Cesare M, *et al.* A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. *J Clin Microbiol* 2020; **58**: e00382-20.
- 22Wymant C, Blanquart F, Golubchik T, *et al.* Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. *Virus Evol* 2018; **4**. DOI:10.1093/ve/vey007.
- 23Siepel AC, Halpern AL, Macken C, Korber BTM. A Computer Program Designed to Screen Rapidly for HIV Type 1 Intersubtype Recombinant Sequences. *AIDS Res Hum Retroviruses* 1995; **11**: 1413–6.
- 24Fogel JM, Bonsall D, Cummings V, *et al.* Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. *J Antimicrob Chemother* 2020; **75**: 3510–6.
- 25Broad Institute. Picard tools. Https://Broadinstitute.Github.Io/Picard/. 2016. https://broadinstitute.github.io/picard/%5Cnhttp://broadinstitute.github.io/picard/.
- 26McGinnis S, Madden TL. BLAST: at the core of a powerful and diverse set of sequence analysis tools. *Nucleic Acids Res* 2004; **32**: W20–5.

- 27Ji H, Enns E, Brumme CJ, *et al.* Bioinformatic data processing pipelines in support of next-
- generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. *J Int AIDS Soc* 2018; **21**: e25193.
- 28Rhee S-Y. Human immunodeficiency virus reverse transcriptase and protease sequence database. *Nucleic Acids Res* 2003; **31**: 298–303.
- 29Shafer RW. Rationale and Uses of a Public HIV Drug‐Resistance Database. *J Infect Dis* 2006; **194**: S51–8.
- 30Liu TF, Shafer RW. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. *Clin Infect Dis* 2006; **42**: 1608–18.
- 31R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Australia, 2020 https://www.R-project.org/ (accessed Dec 11, 2020).
- 32Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *Am J Epidemiol* 2004; **159**: 702–6.
- 33Zeileis A. Object-Oriented Computation of Sandwich Estimators. *J Stat Softw* 2006; **16**. DOI:10.18637/jss.v016.i09.
- 34Zeileis A, Hothorn T. Diagnostic Checking in Regression Relationships. *R News* 2002; **2**: 7– 10.
- 35Halekoh U, Højsgaard S, Yan J. The *R* Package **geepack** for Generalized Estimating Equations. *J Stat Softw* 2006; **15**. DOI:10.18637/jss.v015.i02.
- 36Wickham H, Averick M, Bryan J, *et al.* Welcome to the Tidyverse. *J Open Source Softw* 2019; **4**: 1686.
- 37Wickham H, Chang W, Henry L, *et al.* ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2021 http://ggplot2.org (accessed Feb 8, 2022).
- 38Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'. 2020. https://CRAN.R-project.org/package=cowplot.
- 39Lin Pedersen T. patchwork: The Composer of Plots. 2023. https://cran.r-project.org/web/packages/patchwork/index.html.
- 40FC M, Davis TL, ggplot2 authors. ggpattern: 'ggplot2' Pattern Geoms. 2022. https://github.com/coolbutuseless/ggpattern.
- 41Slowikowski K. ggrepel: Automaticalyl Pposition Non-Overlapping Text Labels with 'ggplot2'. 2023. https://github.com/slowkow/ggrepel.
- 42Wickham H, Bryan J. readxl: Read Excel Files. 2023. https://readxl.tidyverse.org.

- 43Wickham H, Miller E, Smith D. haven: Import and Export 'SPSS', 'Stata' and 'SAS' Files. 2023. https://github.com/tidyverse/haven.
- 44Margot NA, Ram RR, White KL, Abram ME, Callebaut C. Antiviral activity of HIV‐1
- 573 integrase strand-transfer inhibitors against mutants with integrase resistance-associated
- mutations and their frequency in treatment‐naïve individuals. *J Med Virol* 2019; **91**: 2188–94.
- 45Melikian GL, Rhee S-Y, Varghese V, *et al.* Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. *J Antimicrob Chemother* 2014; **69**: 12–20.
- 46Kühnert D, Kouyos R, Shirreff G, *et al.* Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. *PLOS Pathog* 2018; **14**: e1006895.
- 47Namara-Lugolobi E, Namukwaya Z, Owor M, *et al.* Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda. *Afr Health Sci* 2022; **22**. DOI:10.4314/ahs.v22i2.5S.
- 48Arrivé E, Newell M-L, Ekouevi DK, *et al.* Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis†. *Int J Epidemiol* 2007; **36**: 1009–21.
- 49Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. *Lancet Infect Dis* 2013; **13**: 65–76.
- 50Feder AF, Harper KN, Brumme CJ, Pennings PS. Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity. *eLife* 2021; **10**: e69032.
- 51Reynolds SJ, Kityo C, Mbamanya F, *et al.* Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. *Antivir Ther* 2009; **14**: 293–7.
- 52West E, Zeeb M, Grube C, *et al.* Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial. *Clin Infect Dis* 2023; : ciad366.
- 53Huik K, Hill S, George J, *et al.* High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy. *AIDS* 2022; **36**: 1835–40.
- 54Zhang WW, Cheung PK, Oliveira N, Robbins MA, Harrigan PR, Shahid A. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors. *J Infect Dis* 2018; **218**: 1773–6.

- 55George JM, Kuriakose SS, Dee N, *et al.* Rapid Development of High-Level Resistance to
- Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals
- With Baseline Partial Sensitivity to Dolutegravir. *Open Forum Infect Dis* 2018; **5**: ofy221.
- 56Brumme ZL, John M, Carlson JM, *et al.* HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. *PLoS ONE* 2009; **4**: e6687.
- 57Ratmann O, Kagaayi J, Hall M, *et al.* Quantifying HIV transmission flow between high- prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda. *Lancet HIV* 2020; **7**: e173–83.
- 58Kate Grabowski M, Lessler J, Bazaale J, *et al.* Migration, hotspots, and dispersal of HIV infection in Rakai, Uganda. *Nat Commun* 2020; **11**: 976.
- 59Billioux VG, Chang LW, Reynolds SJ, *et al.* Human immunodeficiency virus care cascade
- among sub-populations in Rakai, Uganda: an observational study: Billioux VG et al. *J Int AIDS Soc* 2017; **20**: 21590.
- 60Grabowski MK, Reynolds SJ, Kagaayi J, *et al.* The validity of self-reported antiretroviral use in persons living with HIV: a population-based study. *AIDS* 2018; **32**: 363–9.

Table 1: Total number of participant visits in each survey round stratified by HIV status

Dates listed for each survey round represent the range over which survey visits were conducted. Percentages for each category represent the percentage of all participant visits for that round. Overall viremia was not calculated in round 15 due to missing viral load data. PLWHIV = persons living with HIV.

Table 2: Number of viremic samples at participant visits that had successful drug genotyping for at least one drug.

Percentages show the percentage of all samples within a category that have successful drug resistance genotyping to at least one drug class. p -values generated using the χ^2 test. PLWHIV=people living with HIV.

	NNRTI				NRTI			PI		
Survey round	Prevalence $(95\% \text{ CI})$	Prev. ratio (95% $\mathbf{C}\mathbf{D}$	$p-$ value		Prevalence $(95\% \text{ CI})$	Prev. ratio (95% \mathbf{C}	$p-$ value	Prevalence $(95\% \text{ CI})$	Prev. ratio (95% \mathbf{C}	$p-$ value
15 (2012)	4.97(3.72, 6.65)	ref	ref		1.68(1.07, 2.62)	ref	ref	2.1(1.45, 3.04	ref	ref
16 (2014)	7.35(5.04, 10.71)	1.48 (0.92, 2.38)	0.11		1.48(0.62, 3.57)	0.88 (0.33, 2.37)	0.81	1.9(0.9, 4.01)	0.9(0.39, 2.08)	0.81
17 (2015)	7.15(5.47, 9.35)	1.44 (0.97, 2.14)	0.072		1.85(1.08, 3.19	1.11 (0.55, 2.23)	0.78	1.32(0.69, 2.53)	0.63(0.3, 1.33)	0.22
18 (2017)	9.77(7.35, 12.97)	1.96 (1.31, 2.95)	0.0011		1.76(0.89, 3.51)	1.05 (0.46, 2.39)	0.9	2.02(1.06, 3.86	0.96 (0.46, 2.03)	0.92
19 (2019)	8.77(4.81, 15.99)	1.76 (0.91, 3.44)	0.095		1.65(0.41, 6.62)	0.98 (0.23, 4.23)	0.98	0.83(0.12, 5.81)	0.39 (0.05, 2.86	0.36

Table 3: Estimated prevalence of resistance among viremic pre-treatment PLWHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the $\alpha = 0.05$ level were calculated using the Wald method. PLWHIV = people living with HIV. NNRTI = nonnucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Appendix

Table of Contents

P1…Table of contents

- P2…Supplementary Table 1: Rakai Community Cohort Study survey dates
- P3…Supplementary Figure 1: Rakai Community Cohort Study interview dates
- P4-7…Supplementary methods

P7…Supplementary Table 2: Technology used to generate sequence data by survey round

- P8… Supplementary Table 3: Drugs to which resistance was predicted
- P9-10… Supplementary Table 4: Summary of outcome measures

P11…Supplementary Table 5: Inverse probability weighting model for the probability that genotyping data is available among all viremic PLHIV P12-13… Supplementary Table 6: Inverse probability weighting model for the probability that genotyping data is available among viremic pretreatment PLHIV

P14… Supplementary Table 7: Inverse probability weighting model for the probability that genotyping data is available among viremic treatment-experienced PLHIV

P15…Supplementary Table 8: Inverse probability weighting model for the probability that genotyping data is available among viremic pretreatment seroincident PLHIV

P16… Supplementary Figure 2: Number of participant-visits with resistant predictions for each participant

- P17…Supplementary Table 9: Prevalence of resistance among viremic PLHIV correlation structure model comparison
- P18…Supplementary Table 10: Prevalence of resistance among viremic pre-treatment PLHIV by correlation structure
- P19…Supplementary Table 11: Prevalence of resistance among viremic treatment-experienced PLHIV by correlation structure

P20…Supplementary Table 12: Prevalence of resistance among viremic PLHIV by correlation structure

- P21…Supplementary Table 13: Prevalence of PLHIV, viremic PLHIV, viremic pre-treatment PLHIV, and viremic treatment-experienced PLHIV
- P22…Supplementary Table 14: Number of viremic samples at participant visits that had successful genotyping for all INSTIs
- P23…Supplementary Table 15: Number of viremic samples at participant visits that had successful genotyping for all NNRTIs

P24…Supplementary Table 16: Number of viremic samples at participant visits that had successful genotyping for all NRTIs

P25…Supplementary Table 17: Number of viremic samples at participant visits that had successful genotyping for all PIs

P26…Supplementary Table 18: Number of viremic samples that had resistant genotypes for all drug classes

P27…Supplementary Table 19: Number of viremic samples at participant visits that had successful genotyping for all NNRTIs, NRTIs, and PIs

- P28…Supplementary Table 20: Number of viremic samples at participant visits that had successful genotyping for all drug classes
- P29…Supplementary Table 21: Population prevalence of viremic pre-treatment NNRTI, NRTI, and PI resistance

P30…Supplementary Figure 3: Prevalence of NNRTI, NRTI, and PI resistance among viremic PLHIV in survey round 18, stratified by treatment exposure

P31…Supplementary Table 22: Population prevalence of viremic treatment-experienced NNRTI, NRTI, and PI resistance

P32…Supplementary Table 23: Population prevalence of viremic NNRTI, NRTI, and PI resistance

P33…Supplementary Figure 4: Prevalence of NNRTI resistance among viremic pre-treatment PLHIV stratified by sex, age category, and community type

P34-35…Supplementary Table 24: Prevalence of NNRTI resistance among viremic pre-treatment PLHIV stratified by sex, age category, and community type

P36…Supplementary Table 25: Prevalence of NNRTI resistance among seroincident, pre-treatment PLHIV

P37…Seroincident sub-analysis power calculation

P38…Supplementary Table 26: Prevalence of NNRTI, NRTI, and PI resistance among viremic treatment-experienced PLHIV

P39…Supplementary Figure 5: Patterns of multi-class resistance in Rakai Community Cohort Study, 2017

- P40…Supplementary Table 27: Prevalence of NNRTI single- and multi-class resistance among PLHIV
- P41…Supplementary Table 28: Population prevalence of NNRTI, NRTI, and PI resistance in survey round 18 stratified by community
- P42-43…Supplementary Table 29: Population prevalence of NNRTI, NRTI, and PI resistance in survey round 18 stratified by community

P44-45…Supplementary Table 30: Prevalence of amino acid substitutions among viremic pre-treatment PLHIV

P46…Supplementary Table 31: Prevalence of rtK103N among viremic pre-treatment PLHIV stratified by sex

P47…Supplementary Table 32: Prevalence of amino acid substitutions among viremic treatment-experienced PLHIV

P48… Supplementary Table 33: Prevalence of inT97A among viremic pre-treatment PLHIV by correlation structure

P49…Supplementary Figure 6: Prevalence of inT97A among viremic pre-treatment PLHIV stratified by sex, age category, community type, and subtype

P50-51…Supplementary Table 34: Prevalence of inT97A among viremic pre-treatment PLHIV stratified by sex, age category, community type, and subtype

P52…Supplementary Figure 7: Subtype of viremic pre-treatment PLHIV stratified by presence/absence of inT97A

- P53…Supplementary Figure 8: Virological characteristics of viremic pre-treatment PLHIV stratified by presence/absence of inT97A
- P54…Supplementary references

Supplementary Table 1: Rakai Community Cohort Study survey dates

Start, mid (median), and end dates for each RCCS survey round. Viral load and sequencing data used in this study were collected during R15-19. R19 sequence data was generated for participant visits through 2019-05-17.

Supplementary Figure 1: Rakai Community Cohort Study interview dates

Number of interviews conducted each month, stratified by Rakai Community Cohort Study round.

Supplementary Methods

HIV deep sequencing

For samples taken at participant visits during survey rounds 15 and 16 RNA extraction was performed at University College London Hospital (London, United Kingdom) using the QIAsymphony SP workstation with the QIAsymphony DSP Virus/Pathogen Kit (Qiagen, Hilden, Germany). Following gel electrophoresis confirmation of amplification samples were sequenced at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) on Illumina MiSeq and HiSeq platforms.

For the remaining survey rounds, RNA extraction was performed as above at the Oxford Genomics Centre (Oxford, United Kingdom) followed by library preparation with the SMARTer Stranded Total RNA-Seq kit v2 – Pico Input Mammalian (Clontech, TakaRa Bio). Streptavidin-conjugated beads were used to isolate fragments shorter than 400 nucleotides and PCR amplification and purification was performed with the Agencourt AMPure XMP (Beckman Coulter) following the veSEQ-HIV protocol.¹The Oxford Genomics Centre generated 350 to 600 base pair reads using the Illumina NovaSeq 6000 instrument. A subset of poorly-sequenced treatment-naïve samples from rounds 15 and 16 were also sequenced using this protocol (appendix p 7).

Outcome measures

A summary of primary outcome measures and corresponding figure references is provided in table S4 (appendix pp 9-10).

Population prevalence of all PLHIV, viremic PLHIV, viremic pre-treatment PLHIV, and viremic treatmentexperienced PLHIV in RCCS

We define the prevalence of all PLHIV within a given round as the percentage of all participant-visits in that round from individuals with a serologically confirmed HIV infection as described in *Methods*. The prevalence of viremic PLHIV within a given survey round is defined as the percentage of all participants with a positive HIV test result and measured viral load \geq 1,000 copies/mL at that survey round. Due to a high proportion of missing viral loads in survey round 15, we did not attempt to quantify the prevalence of viremic HIV or treatment experienced viremic HIV during this round. Within each survey round, pre-treatment PLHIV were identified as those who participants with a serologically confirmed HIV infection who self-report never having taken ART within that round and at all previous rounds in which that individual participated in the study. Participant-visits contributed by treatmentexperienced PLHIV were identified as those with a serologically confirmed HIV infection who self-reported ever having taken ART at the current survey round round or at any previous round.

Prevalence of viremic pre-treatment resistance

In this study, individuals with serologically confirmed HIV infection who self-reported never having taken ART (at the current or any other prior survey) were classified as pre-treatment PLHIV. Using robust log-Poisson regression we estimated the prevalence of NNRTI, NRTI, and PI resistance among viremic pre-treatment PLHIV stratified by survey round (R15 – R19) using predicted resistance among all viremic pre-treatment participant visits with available resistance prediction to each class. Drug classes with significant temporal trends among pre-treatment PLHIV were further stratified by age category ((14,24], (24,34], (34,50]), sex (F/M), and community type (agrarian/fishing/trading). Using data from all viremic pre-treatment participant visits with available resistance predictions, non-viremic pre-treatment PLHIV, treatment-experienced PLHIV, and participants not living with HIV we further calculated the population prevalence of viremic pre-treatment NNRTI, NRTI, and PI resistance among all RCCS participants irrespective of HIV serostatus. IPW was used to account for missing resistance data among some viremic pre-treatment PLHIV.

Weights were calculated among pre-treatment PLHIV by first fitting a log-Poisson regression model for each drug class (NNRTI, NRTI, PI) to estimate the probability that resistance prediction was available based on availability of a viral load measurement (True/False), \log_{10} copies/mL among samples with viral load measurements, community type (agrarian/fishing/trading), age category ((14,24]/(24,34]/(34,50]), and sex (M/F) stratified by survey round (appendix pp 12-13). Among participant visits from viremic pre-treatment PLHIV with resistance predictions, weights were calculated as the inverse of the modeled probability of having a resistance prediction normalized such that the sum of the weights within a given drug class and survey round was equal to the number of viremic pretreatment PLHIV in that survey round. When estimating the prevalence of pre-treatment resistance among all participants, people not living with HIV (PNWHIV), treatment-experienced PLHIV, and non-viremic pre-treatment PLHIV were assigned a weight of 1.

Pre-treatment seroincident cases between rounds 15 and 19 were identified through repeat, longitudinal serologic testing. Specifically, at each visit they were classified as participants testing HIV seropositive for the first time and not reporting ART use with an HIV seronegative test result at the prior visit. We used the subset of these individuals with available NNRTI resistance data in their first seropositive round to estimate the prevalence of NNRTI resistance among seroincident PLHIV in each round. The probability of resistance was modelled as a function of seroconversion survey round using robust log-Poisson regression. IPW was used to account for missing sequence data among seroincident PLHIV as described above.

For all pre-treatment participant-visits from seroincident PLHIV we modeled the probability that NNRTI resistance prediction was available for that visit based on the same predictors as above, excluding community type due to a relatively small number of seroincident PLHIV, also using log-Poisson regression. Regression coefficients were used to calculate the probability that resistance prediction was unavailable for each participant-visit based on these predictors (appendix pp 15).

Next, the probability that at least one NNRTI resistance prediction was available for each seroincident PLHIV was calculated as the complement of the product of the probability that no sequence data was available for all of their visits. The inverse of this probability was taken as the weight for each sero-incident individual with available NNRTI resistance prediction. Weights were normalized such that the sum of the weights equaled the total number of seroincident individuals.

Prevalence of all viremic resistance

In survey rounds 17 and 18 we estimated the population prevalence of viremic PLHIV with NNRTI, NRTI, and PI resistant genotypes, regardless of treatment status, using robust log-Poisson regression. Within each drug class models were fit to data from viremic PLHIV with resistance predictions to that drug, non-viremic PLHIV, and participants not living with HIV, again using IPW to account for missing resistance data.

Weights were calculated by modeling the probability of having NNRTI, NRTI, and PI resistance prediction based on the same predictors as above using log-Poisson regression (appendix p 11). Weights were taken as the inverse of the modeled probability for participants-visits with resistance predictions, normalized to the total number of viremic PLHIV in each round. When estimating prevalence among all participants, people not living with HIV and nonviremic PLHIV were assigned a weight of 1.

Prevalence of viremic treatment-experienced resistance

The prevalence of NNRTI, NRTI, and PI resistance among viremic treatment-experienced PLHIV in rounds 17 and 18 was estimated using robust log-Poisson regression among participant-visits with available resistance prediction data to a given class using IPW to account for missing resistance predictions. The population prevalence of viremic treatment-experienced resistance in rounds 17 and 18 was calculated among all viremic treatment-experienced PLHIV, non-viremic treatment-experienced PLHIV, pre-treatment PLHIV, and participants not living with HIV with IPW to approximate the population of all RCCS participants.

Among participant-visits from viremic treatment-experienced PLHIV the probability of having NNRTI, NRTI, and PI resistance prediction was modeled based on the same predictors as above using log-Poisson regression (appendix p 14). Weights were taken as the inverse of the modeled probability for participants-visits with resistance predictions, normalized to the total number of viremic treatment-experienced PLHIV in each round. When estimating population-prevalence, people not living with HIV, pre-treatment PLHIV, and non-viremic treatmentexperienced PLHIV were assigned a weight of 1.

Repeated measures

Correlation between repeated measures from the same participant were evaluated using geepack v.1.3.9.2 We evaluated the impact of the assumed correlation structure on the estimated prevalence of resistance among viremic pre-treatment PLHIV, viremic treatment-experienced PLHIV, and all viremic PLHIV. Independent, exchangeable, AR1, and unstructured correlation structures were evaluated among viremic pre-treatment PLHIV in round 15 through 19 and independent and exchangeable correlation structures were evaluated among viremic treatmentexperienced and all viremic PLHIV in round 17 and 18 (appendix pp 17-21). Due to the limited number of repeated measures, the QIC and CIC values were highly similar regardless of correlation structure. Further, the independent

correlation structure generated the widest confidence intervals. Consequently, independent correlation structure with a robust variance was assumed for all downstream analyses.

Identification of multi-class resistance

Among participant-visits from viremic PLHIV with genotype data for all NNRTIs, NRTIs, and PIs we tabulated the number of participants with all potential combinations of susceptibility/resistance for these three drug classes stratified by whether those participant-visits were pre-treatment or treatment-experienced. Further, in survey round 18 we estimated the prevalence of NNRTI single-class and multi-class resistance among all viremic PLHIV using robust log-Poisson regression with inverse probability weighting to account for the availability of resistance prediction to all NNRTI, NRTI, and PIs.

Weights were calculated by modeling the probability of having a resistance prediction to all NNRTIs, NRTIs, PIs, and INSTIs based on the same predictors as above among viremic pre-treatment and viremic treatment experienced round 18 participants using log-Poisson regression (appendix p 11). Weights were taken as the inverse of the modeled probability for participants-visits with resistance predictions, normalized to the total number of viremic pre-treatment and viremic treatment-experienced participants in each round.

Prevalence of viremic HIV and viremic resistance stratified by community

Robust log-Poisson regression was used to estimate the prevalence of viremic HIV among round 18 participants stratified by community type and individual community ID. Using data from round 18 participants who were not living with HIV, non-viremic PLHIV, and viremic PLHIV with available resistance we further estimated the prevalence of resistant viremia stratified by community type and community ID. When estimating the prevalence of viremic resistance IPW was used to account for the fact that some viremic PLHIV were missing resistance predictions.

Among participant-visits from viremic PLHIV, the probability of having NNRTI, NRTI, and PI resistance prediction was modeled based on the same predictors as above using log-Poisson regression. Weights were taken as the inverse of the modeled probability for participants-visits with resistance predictions, normalized to the total number of viremic PLHIV in each round. Participants not living with HIV non-viremic PLHIV were assigned a weight of 1.

Using the modeled prevalence of NNRTI, NRTI, and PI resistance among all viremic PLHIV we calculated the expected prevalence of resistant viremia among all participants, regardless of HIV status, as a product of the prevalence of resistance among viremic PLHIV and theoretical prevalence of viremia measures up to 16.5%.

Prevalence of amino acid substitutions associated with drug resistance

We first tabulated the number of participant visits contributed by viremic PLHIV between rounds 15 and 19 in which each individual drug resistance substitution was observed. Next, using pre-treatment viremic participant-visits in rounds 15 through 19 in which a resistance prediction was available for all drugs we estimated the prevalence of each individual amino acid substitution stratified by round using robust log-Poisson regression. IPW was used to adjust for missing resistance predictions among some pre-treatment viremic participant visits.

Using treatment-experienced viremic round 18 participants with resistance prediction to at least one drug we estimated the prevalence of each resistance substitution using robust log-Poisson regression. IPW was used to account for missing resistance predictions among some treatment-experienced viremic round 18 participants.

Weights were calculated by modeling the probability of having a resistance prediction to at least one drug based on the same predictors as above among viremic pre-treatment and viremic treatment experienced round 18 participants using log-Poisson regression (appendix pp 12-14). Weights were taken as the inverse of the modeled probability for participants-visits with resistance predictions, normalized to the total number of viremic pre-treatment and viremic treatment-experienced participants in each round.

The prevalence of the inT97A substitution among viremic pre-treatment PLHIV was further stratified by participant sex, age category, community type, and best-reference subtype in each round using robust log-Poisson regression with IPW as above. To stratify inT97A prevalence by subtype, best-reference subtypes observed in less than 300 participant-visits between round 15 and 19 were grouped into "other" categories based on whether they were clonal or recombinant subtypes. The stratified prevalence of inT97A was only estimated in the three most common

subtypes (subtypes A, D, and recombinant). We further tabulated the total number of participant-visits contributed by viremic PLHIV with and without the inT97A substitution stratified by best reference subtype, genome subtype, and polymerase subtype grouping all subtypes with less than three non-inT97A samples into "other." The distribution of log₁₀ viral load measurements of all viremic participant-visits was calculated in 0.2 log10 copies/mL bins stratified by presence/absence of inT97A. The distribution of within-host frequency for inT97A and all other resistance substitutions was calculated in 5% bins and the distribution of support reading counts for inT97A and all other resistance substitutions was calculated in 1000 read bins.

Supplementary Table 2: Technology used to generate sequence data by survey round

Supplementary Table 3: Drugs to which resistance was predicted

 $NNRTI = non-nucleoside$ reverse transcriptase inhibitors. $NRTI = nucleoside$ reverse transcriptase inhibitors. $PI =$ protease inhibitors.

Supplementary Table 4: Summary of outcome measures

Measure refers to how a given analysis is referred to in text, figures, and tables. The model outcome is the participant-visit level characteristic which is being modeled in each analysis. The population is the data among which a given outcome is modeled. Pseudo-population is the population which is being approximated using IPW. Model predictors are the variables included in each model. \overrightarrow{PLHIV} = people living with \overrightarrow{HIV} . NNRTI = nonnucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors. INSTI = integrase strand transfer inhibitors. IPW = inverse probability weighting.

Supplementary Table 5: Inverse probability weighting model for the probability that genotyping data is available among viremic PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. Round 17 participant-visits from women aged 14 to 24 in Agrarian communities with a log_{10} viral load of 0 was used as the reference category. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Supplementary Table 6: Inverse probability weighting model for the probability that genotyping data is available among viremic pre-treatment PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. Round 15 participant-visits from women aged 14 to 24 in Agrarian communities with a log_{10} viral load of 0 was used as the reference category. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors. INSTI = integrase strand transfer inhibitors. All drug classes = genotype data for all INSTIs, NNRTIs, NRTIs, and PIs.

Supplementary Table 7: Inverse probability weighting model for the probability that genotyping data is available among viremic treatment-experienced PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. Round 17 participant-visits from women aged 14 to 24 in Agrarian communities with a log_{10} viral load of 0 was used as the reference category. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors. All drug classes = genotype data for all INSTIs, NNRTIs, NRTIs, and PIs.

Supplementary Table 8: Inverse probability weighting model for the probability that genotyping data is available among seroincident viremic pre-treatment PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the $\alpha = 0.05$ level were calculated using the Wald method. Women aged 14 to 24 in Agrarian communities with a log₁₀ viral load of 0 whose earliest drug resistance prediction was from round 15 was used as the reference category. $PLHIV =$ people living with HIV . NNRTI = non-nucleoside reverse transcriptase inhibitors.

Supplementary Figure 2: Number of participant-visits with resistant predictions for each participant

Pre-treatment data include survey rounds 15 through 19. Viremic treatment-experienced and all viremic data include survey rounds 17 and 18. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. $PI =$ integrase inhibitors.

Supplementary Table 9: Prevalence of resistance among viremic PLHIV correlation structure model comparison

Estimates were generated using robust log-Poisson regression with generalized estimating equation. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors. QIC = quasi information criterion, CIC = correlation information criterion.

Supplementary Table 10: Prevalence of resistance among viremic pre-treatment PLHIV by correlation structure

Estimates were generated using robust log-Poisson regression with generalized estimating equation. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Supplementary Table 11: Prevalence of resistance among viremic treatment-experienced PLHIV by correlation structure

Estimates were generated using robust log-Poisson regression with generalized estimating equation. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Supplementary Table 12: Prevalence of resistance among viremic PLHIV by correlation structure

Estimates were generated using robust log-Poisson regression with generalized estimating equation. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Supplementary Table 13: Prevalence of PLHIV, viremic PLHIV, viremic pre-treatment PLHIV, and viremic treatment-experienced PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. PLHIV = people living with HIV.

Supplementary Table 14: Number of viremic samples at participant visits that had successful genotyping for all INSTIs

Percentages show the percentage of all samples within a category that have successful genotyping for all INSTIs. *p*values generated using the χ^2 test. PLWHIV=people living with HIV. INSTI = integrase strand transfer inhibitors.

Supplementary Table 15: Number of viremic samples at participant visits that had successful genotyping for all NNRTIs

Percentages show the percentage of all samples within a category that have successful genotyping for all NNRTIs. *p*-values generated using the χ^2 test. PLWHIV=people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors

Supplementary Table 16: Number of viremic samples at participant visits that had successful genotyping for all NRTIs

Percentages show the percentage of all samples within a category that have successful genotyping for all NRTIs. *p*values generated using the χ^2 test. PLWHIV=people living with HIV. NRTI = nucleoside reverse transcriptase inhibitors

Supplementary Table 17: Number of viremic samples at participant visits that had successful genotyping for all PIs

Percentages show the percentage of all samples within a category that have successful genotyping for all PIs. *p*values generated using the χ^2 test. PLWHIV=people living with HIV. PI = protease inhibitor.

Supplementary Table 18: Number of viremic samples that had resistant genotypes for all drug classes

Supplementary Table 19: Number of viremic samples at participant visits that had successful genotyping for all NNRTIs, NRTIs, and PIs

Percentages show the percentage of all samples within a category that have successful genotyping for all INSTIs, NNRTI, NRTIs, and PIs. *p*-values generated using the χ^2 test. PLWHIV=people living with HIV. NNRTI = nonnucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Percentages show the percentage of all samples within a category that have successful genotyping for all INSTIs, NNRTI, NRTIs, and PIs. *p*-values generated using the χ^2 test. PLWHIV=people living with HIV. NNRTI = nonnucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Supplementary Table 21: Population prevalence of viremic pre-treatment NNRTI, NRTI, and PI resistance

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Supplementary Figure 3: Prevalence of NNRTI, NRTI, and PI resistance among viremic PLHIV in survey round 18, stratified by treatment exposure

Supplementary Table 22: Population prevalence of viremic treatment-experienced NNRTI, NRTI, and PI resistance

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. NNRTI = non-nucleoside reverse transcriptase inhibitors. $NRTI$ = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Supplementary Table 23: Population prevalence of viremic NNRTI, NRTI, and PI resistance

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the $\alpha = 0.05$ level were calculated using the Wald method. NNRTI = non-nucleoside reverse transcriptase inhibitors. $NRTI$ = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. For visual clarity, points are jittered along the x-axis. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors.

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors.

Supplementary Table 25: Prevalence of NNRTI resistance among seroincident, pretreatment PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors.

Seroincident sub-analysis power calculation

Based on the population-level analysis, we estimate that 9.77% of pre-treatment PLHIV in round 18 had NNRTI-resistant genotypes compared to 4.98% in round 15.

Assuming normality, we let $p_1 = 0.0498$ and $p_2 = 0.0977$. At the $\alpha = 0.05$, $\beta = 0.80$ level we can calculate the number of samples we would need at each time point to have sufficient power to detect this difference using the equation³:

$$
n = (Z_{\frac{\alpha}{2}} + Z_{\frac{\beta}{2}})^2 \frac{(p_1(1-p_1) + p_2(1-p_2))}{(p_1 - p_2)^2}
$$

We thus calculate that we would need a sample size of $n = 432$ at each time point. In the seroincident analysis in Supplementary Table 17 we have data from 39, 32, 67, 59, and 26 PLHIV in rounds 15 through 19, respectively.

Supplementary Table 26: Prevalence of NNRTI, NRTI, and PI resistance among viremic treatment-experienced PLHIV

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. *p*-values that coefficients are different from 0 at the α = 0.05 level were calculated using the Wald method. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

viremic round 18

Multi-class resistance patterns among 137 round 18 participant visits with resistance prediction for all NNRTIs, NRTIs, and PIs with resistance to at least one of the three classes. PLHIV = people living with HIV. NNRTI = nonnucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = integrase inhibitors.

Supplementary Table 27: Round 18 prevalence of NNRTI single- and multi-class resistance among PLHIV

Supplementary Table 28: Population prevalence of NNRTI, NRTI, and PI resistance in survey round 18 stratified by community type

Estimates generated using robust log-Poisson regression. 95% confidence intervals around the mean value generated using the Wald method. Expected values generated using the mean and 95% CI for the prevalence of resistance among viremic PLHIV across all community types extrapolated to the estimated mean prevalence of viremia within individual community types. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Supplementary Table 29: Population prevalence of NNRTI, NRTI, and PI resistance in survey round 18 stratified by community

Estimates generated using robust log-Poisson regression. 95% confidence intervals around the mean value generated using the Wald method. Expected values generated using the mean and 95% CI for the prevalence of resistance among viremic PLHIV across all community types extrapolated to the estimated mean prevalence of viremia within individual community types. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors. PI = protease inhibitors.

Only the 15 most prevalent substitutions in round 18 are shown. Estimates generated using robust log-Poisson regression. 95% confidence intervals around the mean value generated using the Wald method. Expected values generated using the mean and 95% CI for the prevalence of resistance among viremic PLHIV across all community types extrapolated to the estimated mean prevalence of viremia within individual community types. PLHIV = people living with HIV. RT = reverse transcriptase. IN = integrase. PR = protease.

Supplementary Table 31: Prevalence of rtK103N among viremic pre-treatment PLHIV stratified by sex

Only the 15 most prevalent substitutions in round 18 are shown. Estimates generated using robust log-Poisson regression. 95% confidence intervals around the mean value generated using the Wald method. Expected values generated using the mean and 95% CI for the prevalence of resistance among viremic PLHIV across all community types extrapolated to the estimated mean prevalence of viremia within individual community types. PLHIV = people living with HIV. RT = reverse transcriptase. IN = integrase. PR = protease.

Supplementary Table 33: Prevalence of inT97A among viremic pre-treatment PLHIV by correlation structure

Estimates were generated using robust log-Poisson regression with generalized estimating equation. PLHIV = people living with HIV. NNRTI = non-nucleoside reverse transcriptase inhibitors. NRTI = nucleoside reverse transcriptase inhibitors.

Supplementary Figure 6: Prevalence of inT97A among viremic pre-treatment PLHIV stratified by sex, age category, community type, and subtype

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. Only the three most common subtypes are shown. Subtypes were inferred by identifying the closest reference match to each sequenced sample. For visual clarity, points are jittered along the x-axis.

Supplementary Table 34: Prevalence of inT97A among viremic pre-treatment PLHIV stratified by sex, age category, community type, and subtype

Estimates were generated using robust log-Poisson regression. 95% confidence intervals indicate the Wald confidence interval around the mean value in each category. Only the three most common subtypes are shown. Subtypes were inferred by identifying the closest reference match to each sequenced sample.

Supplementary Figure 7: Subtype of viremic pre-treatment PLHIV stratified by presence/absence of inT97A

Subtyping was done by identifying the closest reference match (A), using the whole genome (B), or using only the pol gene (C). Only subtypes observed in ≥ 3 sequences are shown. PLHIV = people living with HIV. In = integrase.

Supplementary Figure 8: Virological characteristics of viremic pre-treatment PLHIV stratified by presence/absence of inT97A

(A,B) Viral load of samples in which we do not (A) and do (B) identify inT97A. Samples with missing viral loads are removed. (C,D) Sequencing read frequency of identified non-inT97A (C) and inT97A (D) drug resistance substitutions. (E,F) Supporting sequencing read count of identified non-inT97A (E) and inT97A (F) drug resistance substitutions. In $=$ integrase.

Supplementary References

- 1Bonsall D, Golubchik T, de Cesare M, *et al.* A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. *J Clin Microbiol* 2020; **58**: e00382-20.
- 2Halekoh U, Højsgaard S, Yan J. The *R* Package **geepack** for Generalized Estimating Equations. *J Stat Softw* 2006; **15**. DOI:10.18637/jss.v015.i02.
- 3Wohl S, Lee EC, DiPrete BL, Lessler J. Sample Size Calculations for Variant Surveillance in the Presence of Biological and Systematic Biases. 2022; published online Jan 1. DOI:10.1101/2021.12.30.21268453.